This article, written with co-authors Bruce H. Kobayashi, Joshua D. Wright, and Douglas H. Ginsburg, examines the economics of litigation and settlement of patent disputes arising from Paragraph IV Abbreviated New Drug Application (ANDA) filings under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) within the framework set out in Actavis.
Aggregate royalty for cellular SEPs in recent court decisions
This academic paper, “Aggregate Royalty for Cellular SEPs in Recent Court Decisions,” published in GRUR Patent by CRA Competition experts Nadia Soboleva and...